News about Adicet Bio Inc

Adicet Bio Pioneers in Gamma Delta T Cell Therapy to Reveal Landmark Innovations at ASGCT 2025 Amidst Head...
Apr 29 2025
Redwood City, Calif. & Boston In a significant development in the biotechnology sector, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnol...

Adicet Bios FDA Fast Track Designation for ADI-001 A Ray of Hope for Systemic Sclerosis Amidst Competitive Revenu...
Feb 27 2025
Redwood City, CA & Boston In a significant development for patients suffering from systemic sclerosis (SSc), Adicet Bio, Inc. (Nasdaq: ACET), a pion...

Adicet Bio Marks Key Advances in Cancer Treatment with Success in Phase 1 Trials for ADI-270 and Promising Biomarke...
Dec 19 2024
Adicet Bio, Inc. a pioneering biotechnology firm focused on the development of allogeneic gamma delta T cell therapies, has made significant strides i...

Adicet Bios ADI-270 Enrollment Launch A Promising Step in the Fight Against Advanced Renal Cell Carcinoma,
Nov 19 2024
In the ever-evolving landscape of oncology, the race to find effective treatments for solid tumors remains an urgent challenge, particularly for metas...

ADI-001 A Promising Off-the-Shelf CAR T Cell Therapy Augmenting Treatment for Autoimmune Diseases
Nov 18 2024
Adicet Bio, Inc. a clinical-stage biotechnology firm, is making strides in the field of allogeneic, gamma delta T cell therapies aimed at treating au...

Adicet Bio Presents Clinical Biomarker Data on Off-the-Shelf CAR T Cell Therapy at ACR Convergence 2024, Demonstrat...
Nov 16 2024
Adicet Bio Unveils Promising Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy at ACR Convergence 2024 In a landmark moment for the field o...

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff...
Oct 16 2024
Adicet Bio Secures FDA Approval for Pioneering Trials of ADI-001 in Rare Autoimmune Disorders: Idiopathic Inflammatory Myopathy and Stiff Person Synd...

The Dawn of Therapeutic Valor Adicet Bio, Inc. Unveils ADI-001 Phase 1 Clinical Trial for Autoimmune Salvation,
Sep 30 2024
In an era gleaming with the luminescent glow of scientific inquiry and medicinal advancement, Adicet Bio, Inc., domiciled in the fair hamlets of Redwo...

Robust Tissue Targeting and Immunomodulation The Transformative Potential of ADI-001 in Allogeneic Gamma Delta ...
Sep 19 2024
: Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company, recently revealed compelling clinical biomarker data from the ongoing Phase...

Advancements in Allogeneic Gamma Delta T Cell Therapies Promising Breakthroughs in Cancer and Autoimmune Diseases
Jul 08 2024
In recent groundbreaking developments, Adicet Bio, a clinical stage biotechnology company specializing in allogeneic gamma delta T cell therapies, has...

Headline: ACET Joins Ranks of Prominent Corporations by Announcing Impressive Third Quarter 2023 Effort2.
Nov 10 2023
The Major Pharmaceutical Preparations industry has been closely watched by investors, with larger companies setting the tone for the sector....

Adicet Bio Inc Faces Sharp Profit Decline, with $-0.72 Shortfall per Share in Fiscal Q1 2023
May 11 2023
Adicet Bio Inc, a clinical-stage biotechnology company, recently reported its fiscal first quarter of 2023 financial results. The company posted a sho...